Á lódáil...
Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy
To overcome unsatisfactory results of classical low-dose cytarabine (LDAC) of cytarabine ≤20 mg twice daily (BID) subcutaneously for 10 days for patients with elderly acute myeloid leukemia (eAML), we evaluated a modified LDAC (mLDAC) of cytarabine 20 mg/m(2) BID subcutaneously plus etoposide 50 mg...
Na minha lista:
| Foilsithe in: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
Impact Journals LLC
2017
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5814177/ https://ncbi.nlm.nih.gov/pubmed/29464037 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23629 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|